RoutineFederal RegisterAdded Jul 21, 2026Multi-specialty

Federal Register Notice: Agency Information Collection Activities: Proposed Collection; Comment Request

CMS seeks public comment on proposed data collection activity.

HighFederal RegisterAdded Jul 21, 2026Multi-specialty

Federal Register Final Rule: Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters fo

Typographical corrections to 2027 ACA Benefit & Payment Parameters rule.

CriticalFDAAdded Jul 18, 2026Infectious Disease

FDA Approval: SEROSTIM (SOMATROPIN) — Type 5 - New Formulation or New Manufacturer

Serostim injectable: Part B billing for HIV-wasting therapy.

HighFDAAdded Jul 18, 2026Oncology

FDA Approval: RETEVMO (SELPERCATINIB) — Type 1 - New Molecular Entity

Oral RET inhibitor Retevmo bills under Medicare Part D.

HighFDAAdded Jul 18, 2026Oncology

FDA Approval: REVTORPYK (GEDATOLISIB) — Type 1 - New Molecular Entity

Revtorpyk (gedatolisib) approved; verify billing pathway vs. FDA label.

RoutineFDAAdded Jul 18, 2026Hematology

FDA Approval: STIMATE (DESMOPRESSIN ACETATE) — Type 3 - New Dosage Form

Stimate nasal spray bills under Part D; orphan drug status noted.